fadeucravacitinib   Click here for help

GtoPdb Ligand ID: 14611

Synonyms: compound 3 [US20220259184]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Fadeucravacitinib is the INN for a Janus kinase inhibitor with anti-inflammatory and immunosuppressant potential. The chemical structure was obtained from WHO INN Proposed List 135 (July 2026). The same chemical structure is claimed for TYK2 (the fourth member of the Janus kinase family) inhibitor activity in patent US2022259184A1 (Beijing Innocare Pharma) [1]. It is intended to target the TYK2 JH2 pseudokinase domain, so acts as an allosteric inhibitor. Beijing Innocare have declared an oral TYK2-JH2 inhibitor in their development pipeline, named ICP-488.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 11
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 132.14
Molecular weight 422.44
XLogP 1.38
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CNC(=O)C1=C(C=C(NC(=O)C2CC2)N=N1)NC3=C(C(=CC=C3)C4=NN(C)C=N4)OC([2H])([2H])[2H]
Isomeric SMILES [2H]C([2H])([2H])OC1=C(C=CC=C1NC2=CC(=NN=C2C(=O)NC)NC(=O)C3CC3)C4=NN(C=N4)C
InChI InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i3D3
InChI Key BZZKEPGENYLQSC-HPRDVNIFSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

Immunopharmacology Comments
Inhibiting TYK2 blocks signalling induced by proinflammatory cytokines such as IL-12, IL-23, and Type I interferons. ICP-488 is proposed as a systemic anti-inflammatory/immunosuppressant treatment for autoimmune conditions including plaque psoriasis and primary Sjögren's syndrome.